Drug (F0da0b67 54e8 43d2 B116 Db3152e885d0 01)
Duloxetine
Product Images NDC 69097-298
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 69097-298). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure-1 (F0da0b67 54e8 43d2 B116 Db3152e885d0 02)
This text represents a graph or chart showing the proportion of patients who relapsed over time from randomization. There is no further information available.*
Figure-2 (F0da0b67 54e8 43d2 B116 Db3152e885d0 03)
The text shows a graph representing the proportion of patients with relapse over time, measured in days from randomization. The Y-axis ranging from 0 to 10 indicates the percentage of patients with relapse, while the X-axis ranging from 0 to 200 shows the number of days from randomization. The graph indicates that the proportion of patients with relapse gradually increases over time.*
Figure-3 (F0da0b67 54e8 43d2 B116 Db3152e885d0 04)
Figure-4 (F0da0b67 54e8 43d2 B116 Db3152e885d0 05)
The text appears to be describing a graph depicting the percentage of patients who have improved their pain levels, with a horizontal axis displaying increments of 10 from 0 to 100 and a vertical axis displaying the percentage of patients improved. However, the text includes some unclear and incomplete characters, making it difficult to fully understand the content.*
Figure-5 (F0da0b67 54e8 43d2 B116 Db3152e885d0 06)
Figure-6 (F0da0b67 54e8 43d2 B116 Db3152e885d0 07)
The text represents a graph showing the percentage of patients improved with a placebo and two dosages of a medicine called Duloxetine. The X-axis displays the numerical values ranging from 210 to 290, whereas the Y-axis represents the percentage of patients improved. The graph displays an improvement in patients with Duloxetine compared to the placebo as the line chart of Duloxetine lies above the placebo chart. However, specific values and details on the study are not available.*
Figure-7 (F0da0b67 54e8 43d2 B116 Db3152e885d0 08)
This is a chart that shows the percentage of patients improved based on their level of pain from baseline. There are two data sets being compared, one labeled "Placebo" and the other labeled "DULO 60/1201 once daily." The chart displays the percentage of improvement on the y-axis and the percent improvement in pain from baseline on the x-axis. The chart shows that the DULO 60/1201 once daily treatment had a higher percentage of patients improved than placebo.*
20mg (F0da0b67 54e8 43d2 B116 Db3152e885d0 09)
Duloxetine Delayed-Release Capsules, USP is a medication available in 60 capsule pack. The drug contains 22.4 mg of ket hytrochrie USP or equivalent 120 mg dlceine. The packaging contains a medication guide for the pharmacist to explain the dosage. It comes in a closed container and should be kept out of reach of children. The recommended storing temperature is 25°C (77°F). The manufacturer is Inventia Healthcare Private Limited and is distributed by Cipla USA, Inc. There is no available information on the text "oz1s emoy" and "ww".*
30mg (F0da0b67 54e8 43d2 B116 Db3152e885d0 10)
This is a product description for Duloxetine Delayed-Release Capsules, USP manufactured by Inventia Healthcare Private Limited and distributed by Cipla USA, Inc. The capsules come in a bottle containing 30 capsules and contain 337 mg of duloxetine hydrochloride USP equivalent to 30 mg of duloxetine. The usual dosage should be seen in the accompanying literature. The capsules should be kept out of the reach of children and should not be used if the inner seal is missing or broken. The storage temperature is between 15-30°C (59-86°F).*
60mg (F0da0b67 54e8 43d2 B116 Db3152e885d0 11)
This is a description of a medication labeled as NDC69067-209-02 Rowy Eachcapue containing 67 3mg of ? (unreadable text). The medication is in the form of delayed-release capsules with a dosage of 60mg and is meant for USP Ut Dge sz (unclear text). The capsules come in a pack of 30. The manufacturer of the medication is Inventia Healthcare Private Limited. The label also has a special blue Pantone color and a code for controlled temperature. No further information is available due to several non-English characters.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
